BLAINJECTIONINJECTABLEPriority Review
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase (human recombinant)) by argenx is neonatal fc receptor blockers [moa]. Approved for neonatal fc receptor blocker [epc]. First approved in 2023.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYVGART HYTRULO is a subcutaneous injection combining efgartigimod alfa with recombinant human hyaluronidase, approved June 2023 for myasthenia gravis. It blocks the neonatal Fc receptor to reduce pathogenic autoantibodies, offering a subcutaneous alternative to the intravenous VYVGART formulation. The added hyaluronidase enables subcutaneous delivery and improved patient convenience.
$9MPart D
GrowthGrowing
Early-stage growth product with limited claims volume suggests significant upside potential for commercial teams building market adoption in a specialist immunology space.
Mechanism of Action
Neonatal Fc Receptor Blockers
Pharmacologic Class:
Neonatal Fc Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
Started Mar 2027
25 enrolled
Myasthenia Gravis Generalized
Why This Matters for Your Career
Worked on VYVGART HYTRULO at argenx? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.